Patent ID: 11965039
Assignee: ZP SPV 3 K/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 22:
23. A compstatin analogue according to claim 22 comprising a sequence selected from the group consisting of:, (SEQ ID NO: 214)

Ac-[K*]GSAIC(1)IWQDWGEHRC(1)TEGE-NH2,

(Compound 100)

 

(SEQ ID NO: 215)

Ac-ASGEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*]-[NH2],

(Compound 113)

 

(SEQ ID NO: 216)

Ac-EFC(1)I[1-Me-Trp]QDWGEHRC(1)EGE-[K*]-[NH2],

(Compound 134)

 

(SEQ ID NO: 217)

Ac-EGSAIC(1)IWQDWGEHRC(1)TEG-[K*]-[NH2],

(Compound 101)

 

(SEQ ID NO: 218)

Ac-EGSAYC(1)I[1-Me-Trp]QDWGEH[K*]C(1)[Sar]E-[NH2],

(Compound 103)

 

(SEQ ID NO: 219)

Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EG-[K*]-NH2,

(Compound 104)

 

(SEQ ID NO: 220)

Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*]-NH2,

(Compound 109)

 

(SEQ ID NO: 221)

Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGK-[K*]-NH2,

(Compound 110)

 

(SEQ ID NO: 222)

Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[γGlu]-[K*]-NH2,

(Compound 111)

 

(SEQ ID NO: 223)

Ac-FC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-[K*]-NH2,

(Compound 102)

 

(SEQ ID NO: 224)

Ac-IC(1)IWQDWGEHRC(1)TEG-[K*]-NH2,

(Compound 92, 93, 95, 96, 98)

 

(SEQ ID NO: 225)

Ac-IC(1)IWQDWGEHRC(1)TEGE-[K*]-NH2,

(Compound 94, 97)

 

(SEQ ID NO: 226)

Ac-SAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-[K*]-NH2,

(Compound 105, 106)

 

(SEQ ID NO: 227)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-[K*]-NH2,

(Compound 119)

 

(SEQ ID NO: 228)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2,

(Compound 123)

 

(SEQ ID NO: 229)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGEGGG-[K*]-NH2,

(Compound 129)

 

(SEQ ID NO: 230)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]-[K*]-NH2,

(Compound 138)

 

(SEQ ID NO: 231)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]ES-[K*]-NH2,

(Compound 140)

 

(SEQ ID NO: 232)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2,

(Compound 127, 128)

 

(SEQ ID NO: 233)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGESES-[K*]-NH2,

(Compound 139, 141)

 

(SEQ ID NO: 234)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[γGlu]GGG-[K*]-NH2,

(Compound 132)

 

(SEQ ID NO: 235)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[8-aminooctanoyl]-[K*]-NH2,

(Compound 136)

 

(SEQ ID NO: 236)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[8-aminooctanoyl]E-[K*]-NH2,

(Compound 137)

 

(SEQ ID NO: 237)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGEGGG-[K*]-NH2,

(Compound 130, 131)

 

(SEQ ID NO: 238)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3]ES-[K*]-NH2,

(Compound 142)

 

(SEQ ID NO: 239)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3][Peg3]-[K*]-NH2,

(Compound 126)

 

(SEQ ID NO: 240)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEK[γGlu]GGG-[K*]-NH2,

(Compound 133)

 

(SEQ ID NO: 241)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-[K*]-NH2,

(Compound 135)

 

(SEQ ID NO: 242)

Ac-SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA-[K*]-NH2,

(Compound 120)

 

(SEQ ID NO: 243)

Ac-SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2,

(Compound 124)

 

(SEQ ID NO: 244)

Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-[K*]-NH2,

(Compound 112, 118)

 

(SEQ ID NO: 245)

Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2,

(Compound 117)

 

(SEQ ID NO: 246)

Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*]-NH2,

(Compound 114, 115, 116)

 

(SEQ ID NO: 247)

Ac-SEYC(1)I[1-Me-Trp]QEW[Sar]EHRC(1)[Sar]EK[γGlu]A-[K*]-NH2,

(Compound 121)

 

(SEQ ID NO: 248)

Ac-SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA-[K*]-NH2,

(Compound 122)

 

(SEQ ID NO: 249)

Ac-SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2,

(Compound 125)

 

(SEQ ID NO: 250)

Φ-EGSEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-NH2,

(Compound 107, 108)

 

(SEQ ID NO: 251)

Φ-ESSAIC(1)IWQDWGEHRC(1)TEGE-NH2,

(Compound 99)

 

(SEQ ID NO: 252)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K*]-NH2,

(Compound 143)

 

(SEQ ID NO: 253)

Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]E[Peg3][Peg3]-[K*]-NH2, and

(Compound 144)

 

(SEQ ID NO: 254)

Ac-EFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA[Peg3][Peg3]-[K*]-NH2.

(Compound 145)